10 citations
,
March 2023 in “Journal of Chemistry” New compounds show promise for treating benign prostate hyperplasia with fewer side effects.
April 2016 in “Journal of Investigative Dermatology” A peptide known for reducing wrinkles also effectively inhibits an enzyme linked to skin inflammation and acne.
3 citations
,
December 2018 in “Biomedical and pharmacology journal/Biomedical & pharmacology journal” Compound 3 protects the heart from damage by activating A1-adenosine receptors.
1 citations
,
May 1992 in “Pharmacological Research” 4 citations
,
November 2024 in “Journal of Advanced Research” Targeting NMMHC IIA may help treat blood-brain barrier damage.
February 2006 in “Inpharma Weekly” April 2020 in “The FASEB journal” Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.
June 2023 in “Italian Journal of Medicine” Urotensin II increases growth and VEGF production in rat skin cells by turning on the Wnt-β-catenin pathway.
6 citations
,
October 2024 in “Journal of Family Medicine and Primary Care” Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.
April 2016 in “Journal of The American Academy of Dermatology” Some blood pressure medications are linked to a higher risk of skin cancer.
June 2024 in “Poster presentations” Janus Kinase inhibitors effectively induce remission in Ulcerative Colitis with an acceptable safety profile.
June 2025 in “Asia-Pacific Journal of Molecular Biology and Biotechnology” Papain from papaya may help treat cardiovascular diseases by breaking down fibrin.
25 citations
,
December 2001 in “Expert Opinion on Pharmacotherapy” Potassium channel openers show promise for treating heart disease and other conditions, but more research is needed to fully understand their effects and safety.
January 2024 in “Journal of Crohn's and colitis” Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
Combining dutasteride or finasteride with an α1 blocker is more effective for managing BPH than using either alone.
November 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” TYK2 inhibition may help treat alopecia areata by promoting hair growth and reducing immune response.
February 2026 in “Eduvest - Journal Of Universal Studies” Janus Kinase Inhibitors are promising new treatments for various skin conditions due to their effectiveness and safety.
February 2024 in “Health Sciences” Botulinum neurotoxin A is effective and safe for treating various conditions, but more clinical trials are needed to fully assess its benefits and risks.
April 2025 in “Revista de Ciências da Saúde Nova Esperança” Botulinum Toxin Type A effectively treats various conditions with high patient satisfaction and minimal side effects.
37 citations
,
November 2007 in “Journal of Biological Chemistry” Ku80 is a key receptor for Thymosin β4, affecting cell migration and wound healing.
July 2024 in “Journal of Investigative Dermatology” DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.
66 citations
,
February 2013 in “PeerJ” Activating cannabinoid receptor 1 reduces certain keratin levels, potentially aiding psoriasis treatment.
1 citations
,
March 2009 in “The Journal of Urology” Combination therapy with fesoterodine and doxazosin improves bladder function and delays BPH progression.
56 citations
,
November 1993 in “Journal of The American Academy of Dermatology” Capsaicin cream quickly relieved itching in two patients with brachioradial pruritus.
January 2018 in “Urologe A” Botulinum neurotoxin injections into the pelvic muscles successfully prevented priapism relapse for over six months.
June 2024 in “ESMO Gastrointestinal Oncology” The combination treatment showed a higher response rate but no significant survival benefits.
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.
January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
1 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.